/
| GEL thousands | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| P&L Items | |||||||
| Revenue | Register | Register | Register | Register | Register | 12,703 | Register |
| Adj. Operating Profit² | Register | Register | Register | Register | Register | 1,624 | Register |
| Adj. EBITDA² | Register | Register | Register | Register | Register | 2,263 | Register |
| Net Income | Register | Register | Register | Register | Register | 2,678 | Register |
| Margins & Profitability Ratios (%) | |||||||
| Adj. Operating Profit Margin² | Register | Register | Register | Register | Register | 12.8% | Register |
| Adj. EBITDA Margin² | Register | Register | Register | Register | Register | 17.8% | Register |
| Net Income Margin | Register | Register | Register | Register | Register | 21.1% | Register |
| Balance Sheet Items & Leverage | |||||||
| Total Assets | Register | Register | Register | Register | Register | 19,348 | Register |
| Total Debt³ | Register | Register | Register | Register | Register | 706 | Register |
| Total Debt³ / Adj. EBITDA² | Register | Register | Register | Register | Register | 0.31x | Register |
| Total Equity | Register | Register | Register | Register | Register | 18,201 | Register |
¹ COGS restated for comparability (2023–2025): From 2023 the company's filings include staff costs in cost of sales; they are shown in operating expenses, so cost of sales covers medical materials only, as in 2019-2022.
² Adj. Operating Profit has been adjusted to exclude non-recurring and one-time items. Adj. EBITDA is calculated by adding back D&A expenses to the adjusted operating profit.
³ Total debt includes lease liabilities, where applicable.